Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2− node positive breast cancer—A National Cancer Database study

The 21-gene Recurrence Score (RS) assay is prognostic and predictive of adjuvant chemotherapy benefit in node positive (N+) breast cancer (BC). We sought to evaluate use patterns of RS assay in N+, ER+/HER2− BC and the impact of RS on recommendations for adjuvant chemotherapy. Patients with T1-T4c,N...

Descripción completa

Detalles Bibliográficos
Autores principales: Peethambaram, Prema P., Hoskin, Tanya L., Day, Courtney N., Goetz, Matthew P., Habermann, Elizabeth B., Boughey, Judy C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648884/
https://www.ncbi.nlm.nih.gov/pubmed/29067357
http://dx.doi.org/10.1038/s41523-017-0044-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648884/
https://www.ncbi.nlm.nih.gov/pubmed/29067357
http://dx.doi.org/10.1038/s41523-017-0044-4

Ejemplares similares